![Ashwin Ram](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ashwin Ram
Amministratore Delegato presso Jupiter Therapeutics, Inc.
Posizioni attive di Ashwin Ram
Società | Posizione | Inizio | Fine |
---|---|---|---|
Jupiter Therapeutics, Inc.
![]() Jupiter Therapeutics, Inc. Medical/Nursing ServicesHealth Services Jupiter Therapeutics, Inc. provides health care services. The company is headquartered in Los Alamitos, CA. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Fondatore | - | - |
Corporate Officer/Principal | - | - | |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Direttore operativo | - | - |
Catalys Pacific LLC
![]() Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Investitore di Private Equity | - | - |
Storia della carriera di Ashwin Ram
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Giappone | 2 |
Posizioni
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Settori
Health Services | 3 |
Finance | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Catalys Pacific LLC
![]() Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Finance |
Jupiter Therapeutics, Inc.
![]() Jupiter Therapeutics, Inc. Medical/Nursing ServicesHealth Services Jupiter Therapeutics, Inc. provides health care services. The company is headquartered in Los Alamitos, CA. | Health Services |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Health Services |
- Borsa valori
- Insiders
- Ashwin Ram
- Esperienza